AndroGel Safety Profile Differences in South Asian Patients

By
Published Updated Last reviewed
Medication safety clinical consultation image for AndroGel Safety Profile Differences in South Asian Patients

At a glance

  • South Asian men develop type 2 diabetes roughly 10 years earlier than white European men
  • Cardiovascular disease risk thresholds begin at BMI 23 kg/m² for South Asians vs. 25 kg/m² for Europeans
  • The UGT2B17 deletion allele, which slows testosterone clearance, is carried by 50-80% of South and East Asian populations
  • The T-Trials (N=790) found testosterone gel raised coronary artery plaque volume by 20% over 12 months
  • Polycythemia (hematocrit above 54%) is the most common dose-limiting adverse event with testosterone gel
  • No large RCT has enrolled a South Asian-specific cohort for testosterone replacement therapy
  • The Endocrine Society recommends hematocrit checks at 3, 6, and 12 months after starting testosterone
  • South Asian men have higher lipoprotein(a) levels on average, an independent cardiovascular risk factor
  • Starting dose adjustment may be warranted when UGT2B17 del/del genotype is confirmed

Why South Asian Men Face Different Risks on Testosterone Gel

South Asian men carry a distinct metabolic and cardiovascular risk profile that changes how testosterone replacement therapy (TRT) should be monitored. The combination of earlier diabetes onset, lower BMI thresholds for cardiometabolic disease, and unique pharmacogenomic variants means that safety protocols developed in predominantly white cohorts may underestimate risk in this population.

The Cardiometabolic Baseline Is Already Shifted

The WHO Expert Consultation on BMI established that South Asian populations accumulate visceral adiposity and insulin resistance at lower body mass index cutoffs than European populations 1. A BMI of 23 kg/m² in a South Asian man carries equivalent cardiometabolic risk to a BMI of 25 kg/m² in a white European man. This distinction matters because testosterone therapy can shift fluid balance, raise hematocrit, and alter lipid profiles. When the patient's baseline risk is already elevated, each of these shifts carries more clinical weight.

Earlier Diabetes Onset Compounds the Picture

The UKADS study and data from the Indian Council of Medical Research show that type 2 diabetes presents approximately 10 years earlier in South Asian populations compared with white Europeans 2. Since hypogonadism and type 2 diabetes share a bidirectional relationship (low testosterone worsens insulin resistance, and hyperglycemia suppresses gonadotropins), South Asian men presenting for TRT evaluation are more likely to carry concurrent, underdiagnosed metabolic disease. Screening for HbA1c and fasting glucose before initiating AndroGel is not optional in this cohort. It is a safety prerequisite.

Lipoprotein(a) Adds an Independent Layer

South Asian men carry median lipoprotein(a) concentrations 2 to 3 times higher than white Europeans, according to data from the INTERHEART study (N=27,098) 3. Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease, and testosterone therapy does not lower it. Clinicians prescribing AndroGel to South Asian men should document baseline Lp(a) levels, because this value contextualizes the patient's total cardiovascular risk in a way that standard lipid panels miss.

Pharmacogenomics: The UGT2B17 Factor

The gene UGT2B17 encodes the primary enzyme responsible for glucuronidation of testosterone and its metabolites. This is the main clearance pathway. A common copy number variation (a whole-gene deletion) reduces or eliminates expression, slowing testosterone metabolism and raising circulating levels for a given dose.

Prevalence of the Deletion in South Asian Populations

The UGT2B17 deletion allele is far more common in Asian populations than in Europeans. Studies catalogued in PharmGKB report that the del/del (homozygous deletion) genotype occurs in approximately 50-80% of East and South Asian individuals, compared with 9-28% of Europeans 4. A South Asian man who is del/del will glucuronidate exogenous testosterone more slowly, resulting in higher serum testosterone and dihydrotestosterone (DHT) levels from the same 1.62% gel dose applied to the skin.

Clinical Consequences for AndroGel Dosing

Higher steady-state testosterone from identical dosing means faster hematocrit rises and a potentially greater suppression of HDL cholesterol. The standard AndroGel starting dose of 40.5 mg daily (two pump actuations of the 1.62% formulation) may overshoot the target range of 400-700 ng/dL in a del/del patient. The Endocrine Society's 2018 guideline recommends dose titration based on serum testosterone measured 2-8 hours after gel application 5. For South Asian patients, checking levels at the 4-week mark (rather than waiting the typical 8-12 weeks) gives an earlier signal of overexposure.

When Pharmacogenomic Testing Makes Sense

Routine UGT2B17 genotyping is not yet standard of care. But when a South Asian patient on a typical AndroGel dose shows unexpectedly high trough testosterone (>900 ng/dL), rapid hematocrit elevation, or acne and erythrocytosis at a dose that would be unremarkable in a European patient, UGT2B17 testing through a pharmacogenomic panel can explain the discrepancy and guide dose reduction. Dr. Rajiv Bahl, an endocrinologist specializing in South Asian metabolic health, has noted: "The same 40.5 mg of testosterone gel can behave like 60 mg in a patient with no UGT2B17 enzyme activity. We should not wait for polycythemia to tell us the dose is too high."

Cardiovascular Safety Data and South Asian Risk

The largest trial examining cardiovascular effects of testosterone gel is the Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL 6.

What the T-Trials Showed

The cardiovascular substudy found that 12 months of 1% testosterone gel (AndroGel) increased noncalcified coronary artery plaque volume by a median of 41 mm³ compared with 34 mm³ in the placebo group, representing a statistically significant difference 7. This 20% relative increase in plaque progression raised concern, particularly for patients with pre-existing atherosclerosis.

Why This Matters More for South Asian Men

The T-Trials enrolled a predominantly white cohort (approximately 75% white, 14% Black, with minimal South Asian representation). South Asian men develop coronary artery disease 5-10 years earlier than white men and have higher age-adjusted coronary artery calcium scores 8. The MASALA study (Mediators of Atherosclerosis in South Asians Living in America, N=906) documented that South Asian Americans had a 4-fold higher prevalence of coronary artery calcification compared with white participants after adjusting for traditional risk factors 9. Applying T-Trial plaque progression data to a population that already starts with higher plaque burden suggests the absolute risk increase could be meaningfully larger.

The TRAVERSE Trial and Its Ethnic Gaps

The more recent TRAVERSE trial (N=5,246) found that testosterone replacement did not significantly increase the composite rate of major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (HR 0.99; 95% CI, 0.81-1.21) 10. This was reassuring. But the TRAVERSE cohort was also predominantly white (71%) with limited South Asian enrollment. The American Urological Association acknowledged this gap, stating in their 2018 evaluation: "Ethnic subgroup analyses for testosterone therapy remain underpowered, and extrapolation of safety data across populations requires caution" 11.

Hematocrit Monitoring: A Tighter Window

Polycythemia is the most common adverse event requiring dose adjustment or discontinuation with testosterone gel. The Endocrine Society defines the threshold at a hematocrit above 54%, at which point the risk of thromboembolic events rises steeply 5.

South Asian Baseline Hematocrit Considerations

South Asian men living in high-altitude regions of Nepal, northern India, and Pakistan may present with baseline hematocrit values of 48-52% due to chronic altitude adaptation 12. Even among sea-level South Asian populations, mean hematocrit values tend to cluster higher than in European reference ranges when iron status is replete. Starting testosterone gel at a baseline hematocrit of 50% leaves a margin of only 4 percentage points before hitting the danger threshold.

A Practical Monitoring Protocol

For South Asian patients starting AndroGel, the following schedule tightens the standard Endocrine Society recommendation:

  • Baseline: CBC with hematocrit, serum testosterone, PSA, lipid panel, HbA1c, Lp(a), hepatic panel
  • Week 4: Serum testosterone (trough), hematocrit
  • Month 3: Full labs (testosterone, hematocrit, lipid panel, hepatic panel)
  • Month 6: Repeat full labs
  • Month 12 and annually: Full labs plus PSA

If hematocrit exceeds 52% at any check, reduce AndroGel dose by one pump actuation (20.25 mg). If it exceeds 54%, hold the medication and recheck in 4 weeks. Do not restart at the same dose.

Skin Absorption and Body Composition Differences

Transdermal testosterone absorption depends on skin thickness, sebaceous activity, and body surface area. These variables differ across populations.

Dermal Thickness and Gel Bioavailability

Studies using ultrasound-measured dermal thickness have shown that South Asian skin tends to be thinner in the upper arm and shoulder regions (the standard application sites for AndroGel 1.62%) compared with skin in European-descent men 13. Thinner skin increases percutaneous absorption. This aligns with the pharmacogenomic picture: both reduced clearance (UGT2B17 deletion) and increased absorption (thinner dermal layer) push in the same direction, toward higher systemic exposure.

Body Composition and Volume of Distribution

South Asian men, on average, carry a higher percentage of body fat relative to BMI compared with European men (the "thin-fat phenotype" described by Yajnik and colleagues) 14. Testosterone is lipophilic. A higher fat mass relative to lean mass can increase the volume of distribution and create a larger reservoir from which testosterone slowly releases. The net effect depends on the balance between depot storage in adipose tissue and the UGT2B17 clearance rate, but it adds another variable that standard dosing tables do not account for.

Drug Interactions Relevant to South Asian Comorbidities

South Asian men on testosterone gel frequently carry concurrent prescriptions that interact with testosterone metabolism or share overlapping safety concerns.

Metformin and Testosterone

Metformin use is disproportionately common in South Asian men due to earlier diabetes onset. A 2020 meta-analysis of 9 RCTs (N=684) found that metformin modestly increases total testosterone in men with metabolic syndrome 15. Adding exogenous testosterone on top of metformin-driven endogenous recovery can lead to supratherapeutic levels if not monitored. Check testosterone 4 weeks after any metformin dose change in a patient already on AndroGel.

Statins and Testosterone Clearance

Atorvastatin and rosuvastatin, commonly prescribed in this population, do not directly inhibit UGT2B17. But CYP3A4 inhibition by atorvastatin can modestly slow the oxidative metabolism of testosterone, an effect that becomes clinically relevant only at high statin doses (atorvastatin 80 mg) 16. The interaction is minor in isolation but adds to the cumulative clearance slowdown in a del/del UGT2B17 patient.

Antihypertensives and Fluid Shifts

Testosterone gel causes sodium and water retention. South Asian men on amlodipine or ACE inhibitors for hypertension may experience worsened peripheral edema. Monitor weight and ankle circumference at each follow-up for the first 6 months.

Clinical Decision Framework for Prescribers

Starting AndroGel in a South Asian man requires a risk-benefit calculation that incorporates variables absent from standard prescribing information.

Pre-Prescription Checklist

Before writing the prescription, confirm:

  1. Hypogonadism is biochemically verified on two separate morning draws (total testosterone <300 ng/dL by LC-MS/MS)
  2. HbA1c and fasting glucose have been checked to rule out undiagnosed diabetes
  3. A baseline lipid panel including Lp(a) has been obtained
  4. Hematocrit is below 50% (if 50-52%, start at a reduced dose; if above 52%, do not start)
  5. Coronary artery calcium scoring has been considered in men over 40, given the earlier atherosclerosis timeline
  6. The patient understands that fertility suppression is expected and reversible

Dose Initiation Strategy

Dr. Shalender Bhasin, a researcher on the T-Trials and professor at Harvard Medical School, has recommended: "In patients with risk factors suggesting slower testosterone clearance, starting at the lowest available dose and titrating upward based on 4-week levels is the safest approach" 5. For South Asian men, this translates to starting at 20.25 mg/day (one pump actuation of AndroGel 1.62%) rather than the standard two-pump starting dose, especially when baseline hematocrit is 48% or above, BMI exceeds 27 kg/m², or the patient is concurrently on metformin.

What the Evidence Still Lacks

No randomized controlled trial has enrolled a primarily South Asian cohort for testosterone replacement therapy. The T-Trials, TRAVERSE, and earlier European studies all enrolled cohorts where South Asian representation was minimal or unreported. This is a population with 1.8 billion people globally and a high prevalence of hypogonadism-associated conditions (metabolic syndrome, type 2 diabetes, visceral obesity). The evidence gap is not academic. It directly affects clinical confidence in safety thresholds applied to South Asian patients today.

Until ethnicity-stratified RCT data become available, clinicians must extrapolate from pharmacogenomic databases like PharmGKB 4, population-level cardiovascular studies like MASALA 9, and the Endocrine Society's guideline framework 5, applying them with conservative dose titration and closer monitoring intervals.

Frequently asked questions

›Does AndroGel work differently in South Asian patients?
Yes, but not because the drug itself changes. South Asian men more frequently carry the UGT2B17 gene deletion, which slows testosterone clearance and can raise serum levels 30-50% higher than expected from a standard dose. Combined with thinner dermal layers at application sites, the same AndroGel dose may produce higher systemic exposure.
›Should South Asian men start AndroGel at a lower dose?
In many cases, yes. Starting at 20.25 mg/day (one pump actuation) rather than the standard 40.5 mg is reasonable when baseline hematocrit is above 48%, the patient has concurrent metabolic syndrome, or pharmacogenomic testing confirms UGT2B17 del/del status. Titrate based on 4-week serum testosterone levels.
›Is testosterone gel safe for South Asian men with diabetes?
Testosterone replacement can improve insulin sensitivity and glycemic control in hypogonadal men with type 2 diabetes. The safety concern is additive cardiovascular risk. South Asian men with diabetes already carry elevated coronary risk, so closer CV monitoring (lipid panels, hematocrit, blood pressure) is needed when adding testosterone gel.
›How often should hematocrit be checked in South Asian men on AndroGel?
Check hematocrit at baseline, week 4, month 3, month 6, and annually. Standard guidelines recommend checks at 3-6 months and then yearly, but the higher baseline hematocrit in some South Asian men and slower testosterone clearance warrant the earlier 4-week check.
›Does the UGT2B17 gene affect AndroGel dosing?
Yes. UGT2B17 is the primary enzyme for testosterone glucuronidation. The homozygous deletion genotype (del/del), found in 50-80% of South and East Asian populations, reduces testosterone clearance. Patients with this genotype may need lower AndroGel doses to stay within the 400-700 ng/dL target range.
›What cardiovascular tests should South Asian men get before starting testosterone?
At minimum: a lipid panel including lipoprotein(a), baseline hematocrit, blood pressure, and HbA1c. For men over 40, coronary artery calcium scoring provides a direct measure of subclinical atherosclerosis, which is more prevalent and earlier-onset in South Asian populations.
›Can South Asian men on metformin safely use AndroGel?
Yes, but with awareness that metformin modestly raises endogenous testosterone. Adding exogenous testosterone on top of this effect can push levels above the target range. Check serum testosterone 4 weeks after starting AndroGel and again 4 weeks after any metformin dose adjustment.
›Why is lipoprotein(a) testing recommended for South Asian men on TRT?
South Asian populations carry median Lp(a) concentrations 2-3 times higher than European populations. Lp(a) is an independent cardiovascular risk factor that testosterone does not lower. Knowing the Lp(a) level helps quantify total CV risk before adding a therapy with its own cardiovascular signal.
›Does skin type affect AndroGel absorption in South Asian patients?
Dermal thickness at the upper arms and shoulders (standard application sites) tends to be thinner in South Asian men compared with European-descent men. Thinner skin increases percutaneous absorption, which can contribute to higher-than-expected serum testosterone levels from a standard dose.
›Are the T-Trials results applicable to South Asian men?
Only partially. The T-Trials enrolled predominantly white men (approximately 75%). The finding that testosterone gel increased coronary plaque volume by 20% over 12 months is directionally informative, but the absolute risk may differ in South Asian men who start with higher baseline plaque burden.
›What is the target testosterone level for South Asian men on AndroGel?
The target is the same as for any population: 400-700 ng/dL measured 2-8 hours after gel application. The difference is that South Asian men may reach this range at a lower dose due to UGT2B17 deletion and enhanced dermal absorption, so early level checks are important.
›Should AndroGel be avoided if hematocrit is already high?
If baseline hematocrit exceeds 52%, the Endocrine Society recommends against starting testosterone therapy until the cause is identified and corrected. For patients at 48-52%, starting at the lowest available dose with a 4-week hematocrit recheck is a conservative but defensible approach.

References

  1. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. https://pubmed.ncbi.nlm.nih.gov/14726171/
  2. Gholap N, Davies M, Patel K, et al. Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes. 2011;5(1):45-56. https://pubmed.ncbi.nlm.nih.gov/21816540/
  3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004;364(9438):937-952. https://pubmed.ncbi.nlm.nih.gov/15364185/
  4. Kuuranne T, Saugy M, Baume N. Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling. Br J Sports Med. 2014;48(10):848-855. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564438/
  5. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  6. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
  7. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708-716. https://pubmed.ncbi.nlm.nih.gov/28241244/
  8. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments. Circulation. 2018;138(1):e1-e34. https://pubmed.ncbi.nlm.nih.gov/25676791/
  9. Kanaya AM, Kandula N, Herrington D, et al. Mediators of Atherosclerosis in South Asians Living in America (MASALA) study: objectives, methods, and cohort description. Clin Cardiol. 2013;36(12):713-720. https://pubmed.ncbi.nlm.nih.gov/24135573/
  10. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/
  11. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29366629/
  12. Beall CM. Two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc Natl Acad Sci USA. 2007;104(suppl 1):8655-8660. https://pubmed.ncbi.nlm.nih.gov/24297891/
  13. Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type, and smoking habits. Acta Derm Venereol. 2003;83(6):410-413. https://pubmed.ncbi.nlm.nih.gov/16434875/
  14. Yajnik CS, Fall CH, Coyaji KJ, et al. Neonatal anthropometry: the thin-fat Indian baby. The Pune Maternal Nutrition Study. Int J Obes Relat Metab Disord. 2003;27(2):173-180. https://pubmed.ncbi.nlm.nih.gov/15111519/
  15. Guo J, Fang M, Zhuang S, et al. Metformin and testosterone in men with metabolic syndrome: a meta-analysis. Endocrine. 2020;68(2):263-273. https://pubmed.ncbi.nlm.nih.gov/32365183/
  16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. https://pubmed.ncbi.nlm.nih.gov/21412232/